Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Auranofin and Sirolimus in NSCLC
NCT02126527Phase 1Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Aug 2013
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of auranofin and sirolimus in non-small cell lung cancer (NSCLC) and solid tumor, sponsored by Mayo Clinic. Planned start Aug 2013; status: withdrawn.
02
Drugs
auranofinsirolimus
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT02126527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02126527.